Literature DB >> 10180927

Alternative approaches to valuing intangible health losses: the evidence for multiple sclerosis.

F A Sloan1, W K Viscusi, H W Chesson, C J Conover, K Whetten-Goldstein.   

Abstract

This study uses both risk-risk and risk-dollar approaches to assess intangible health losses associated with multiple sclerosis (MS). Using an estimation approach that adjusts for potential perceptional biases that may effect the expressed risk tradeoffs, we estimated parameters of the utility function of persons with and without MS as well as the degree of subjects" overestimation of the probability of obtaining MS. The sample included subjects from the general population and persons with MS. We found that marginal utility of income is lower in the state with MS than without it. However, the difference in marginal in two states was greater for persons without MS than for those with the disease. Persons with MS overestimated the probability of acquiring MS to a greater extent than did persons within MS. Correcting for overestimation of this probability, the value of intangible loss of a statistical case of MS derived from responses of the general population was US$350,000 to US$500.000. Persons with MS were willing to pay somewhat more than this (D80,118,J17).

Entities:  

Mesh:

Year:  1998        PMID: 10180927     DOI: 10.1016/s0167-6296(97)00025-8

Source DB:  PubMed          Journal:  J Health Econ        ISSN: 0167-6296            Impact factor:   3.883


  15 in total

1.  An experimental test of the concentration index.

Authors:  Han Bleichrodt; Kirsten I M Rohde; Tom Van Ourti
Journal:  J Health Econ       Date:  2012-01-12       Impact factor: 3.883

Review 2.  Cost effectiveness in low- and middle-income countries: a review of the debates surrounding decision rules.

Authors:  Samuel D Shillcutt; Damian G Walker; Catherine A Goodman; Anne J Mills
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

3.  Long-term health investment when people underestimate their adaptation to old age-related health problems.

Authors:  Octave Jokung; Serge Macé
Journal:  Eur J Health Econ       Date:  2012-12-28

4.  Market failure in the pharmaceutical industry and how it can be overcome: the CureShare mechanism.

Authors:  Moshe Levy; Adi Rizansky
Journal:  Eur J Health Econ       Date:  2013-02-17

5.  Household Labor Supply and the Gains from Social Insurance.

Authors:  Itzik Fadlon; Torben Heien Nielsen
Journal:  J Public Econ       Date:  2018-02-02

6.  Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public.

Authors:  Peter A Ubel; George Loewenstein; Christopher Jepson
Journal:  Qual Life Res       Date:  2003-09       Impact factor: 4.147

7.  Advantageous Selection, Moral Hazard, and Insurer Sorting on Risk in the U.S. Automobile Insurance Market.

Authors:  Frank A Sloan; Patricia A Robinson; Lindsey M Eldred
Journal:  J Risk Insur       Date:  2016-11-28

8.  Hesitancy Toward a COVID-19 Vaccine.

Authors:  Linda Thunström; Madison Ashworth; David Finnoff; Stephen C Newbold
Journal:  Ecohealth       Date:  2021-06-04       Impact factor: 3.184

9.  Do preferences of drinker-drivers differ?

Authors:  Frank A Sloan; Lindsey M Eldred
Journal:  Int J Health Econ Manag       Date:  2015-03-22

10.  Willingness to pay for prevention and treatment of lymphatic filariasis in Leogane, Haiti.

Authors:  Richard D Rheingans; Anne C Haddix; Mark L Messonnier; Martin Meltzer; Gladys Mayard; David G Addiss
Journal:  Filaria J       Date:  2004-01-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.